TICKERNERD
Menu
EOCNEOCNHealthcare · Biotechnology

EOCN Stock Forecast: Eocene Ltd. Price Predictions for 2026-2027

Last close, 15 Sept 2026
$3.63
−5.10% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 32 of 100 as at 14 Sept 2026 — in the lower half.

Market cap
$0.00
Ticker Nerd rank
32 / 100
Median analyst target
—
Analysts covering
1
Revenue$0.0
Operating income−$2.8M
Net income−$2.7M
Free cash flow−$2.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.2%
1M
−13.4%
YTD
−39.7%
1Y
−69.0%
From 52W high
−71.9%
From 52W low
0.0%
$4
$13
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

EOCN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Eocene Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Sept 2026
32 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
97
Revisions
82
Accruals
54
Quality
36
Volatility
30
Growth
26
Momentum
26
Issuance
16
Value
6

Size (97): Smaller than most of the companies we track.

Value (6): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

EOCN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on EOCN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$4$6$8$10$12$14Oct 25Jan 26Apr 26Jul 26EOCN

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
0 Buy1 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
4 Apr 2025Maxim GroupDowngradeHold—
24 July 2023Maxim GroupUpgradeBuy—
8 Aug 2022Canaccord GenuityDowngradeHold—
8 Aug 2022Maxim GroupDowngradeHold—
18 May 2022Raymond JamesDowngradeMarket Perform—
3 May 2022HC Wainwright & Co.DowngradeNeutral—
3 May 2022Raymond JamesMaintainsOutperform—
17 May 2021Canaccord GenuityMaintainsBuy—
19 Mar 2021HC Wainwright & Co.MaintainsBuy—
8 Jan 2021Raymond JamesMaintainsOutperform—
25 Nov 2020Canaccord GenuityMaintainsBuy—
22 May 2020B. Riley FBRDowngradeNeutral—
22 May 2020B. Riley SecuritiesDowngradeNeutral—
15 May 2020Raymond JamesMaintainsOutperform—
13 Mar 2020B. Riley FBRMaintainsBuy—
13 Mar 2020B. Riley SecuritiesMaintainsBuy—
13 Mar 2020StifelMaintainsBuy—
4 Feb 2020Craig-HallumInitiatesBuy—
30 Jan 2020Cantor FitzgeraldAssumesOverweight$59 → $14
22 July 2019Laidlaw & Co.InitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. EOCN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

EOCN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 15 Sept 2026, Eocene Ltd. returned −69.0% against +15.9% for the S&P 500, dividends included.

EOCN vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Oct 25Jan 26Apr 26Jul 26EOCNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

EOCN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Eocene Ltd. (EOCN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 74% of US stocks

Price / sales
—
Price / book
0.3×

Cheaper than 88% of US stocks

EV / EBITDA
1.1×

Cheaper than 57% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−68.2%

Higher than 18% of US stocks

Return on assets
−30.2%

Higher than 14% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Eocene Ltd. (EOCN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Eocene Ltd. has a market value of $0.0 and an enterprise value of $0.0.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$11.3M.

  • Free cash flow in the twelve months to 30 June 2026: −$8.5M.

  • Shares outstanding: 125,174.

  • Trailing P/E: 0.0×; forward P/E: −4.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Eocene Ltd. employs 3 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 15 Sept 2026

Data provided by Twelve Data

Peers

EOCN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
EOCNEocene Ltd.$0.00
32
GOVXGeoVax Labs, Inc.$3.9M
39
OSRHOSR Health, Inc.$4.1M
—
MBIOMustang Bio, Inc.$3.9M
13
GRIGRI Bio, Inc.$4.1M
29
CVKDCadrenal Therapeutics, Inc.$3.8M
34
PMCBPharmaCyte Biotech, Inc.$4.2M
29

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Eocene Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest EOCN news & analysis

Galmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol "EOCN" to Reflect its New Dawn Platform for GI Innovation

PRNewsWire · 9 Sept 2026neutral

Galmed Pharmaceuticals is rebranding as EoCene and will trade under the new ticker symbol "EOCN" on the Nasdaq Capital Market, reflecting its new Dawn Platform for gastrointestinal innovation. The company has also terminated its Standby Equity Purchase Agreement with YA II PN, LTD. (Yorkville) effective immediately and regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2).

Why it matters — GLMD watchers would care because the company is undergoing a corporate rebranding with a new ticker symbol, while also resolving its Nasdaq listing compliance and terminating its equity purchase agreement.

Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology

PRNewsWire · 19 Aug 2026positive

Galmed announced successful first-in-human proof-of-concept clinical study results for Colospan's novel intraoperative tissue assessment technology. The prospective, single-arm study enrolled 32 colorectal cancer patients at three clinical centers in Israel and demonstrated feasibility of intraoperative quantitative measurement of colon tissue quality.

Why it matters — Galmed watchers would care because these positive early clinical results for Colospan's technology represent a key development milestone in Galmed's portfolio.

Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models

PRNewsWire · 17 Aug 2026positive

Galmed Pharmaceuticals announced first-time results from prostate oncology studies, reporting that Aramchol demonstrated a 3-4 fold increase in cell death compared to enzalutamide (Xtandi) alone in prostate cancer models. The release also noted Xtandi's global sales figures of approximately $8 billion in 2024 and $6 billion in 2025.

Why it matters — A GLMD watcher would care because these early preclinical results suggest Aramchol could have potential beyond its existing indications, positioning the company in a large oncology market.

Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market

PRNewsWire · 28 July 2026positive

Galmed Pharmaceuticals announced the development of an orally dispersible film (ODF) formulation of its SCD1 inhibitor Aramchol for Parkinson's disease, which showed higher systemic bioavailability and increased central nervous system exposure compared to conventional oral administration in testing.

Why it matters — This development expands Galmed's pipeline beyond liver indications into neurodegenerative disease, potentially opening a new and large addressable market for the company's lead compound.

FAQ

Frequently asked questions about EOCN stock

Is EOCN stock a buy right now?

Of the 1 analysts covering Eocene Ltd., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Eocene Ltd. 32 out of 100 across roughly 4,600 US stocks as at 14 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank EOCN?

As at 14 Sept 2026, Eocene Ltd. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).

What is the EOCN stock forecast for 2030?

No analyst covering Eocene Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EOCN are extrapolating price history, which says nothing about the business.

How has EOCN stock performed over the past year?

Eocene Ltd. returned -69.0% over the 12 months to 15 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Eocene Ltd. do?

Eocene Ltd. is an Israel-based biopharmaceutical and medtech company focused on gastrointestinal disease management and related therapeutic areas.

What is the latest news on EOCN?

The most recent item we track (PRNewsWire, 9 Sept 2026): "Galmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol "EOCN" to Reflect its New Dawn Platform for GI Innovation". Galmed Pharmaceuticals is rebranding as EoCene and will trade under the new ticker symbol "EOCN" on the Nasdaq Capital Market, reflecting its new Dawn Platform for gastrointestinal innovation. The company has also terminated its Standby Equity Purchase Agreement with YA II PN, LTD. (Yorkville) effective immediately and regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2).

Company

About Eocene Ltd.

Eocene Ltd. is an Israel-based biopharmaceutical and medtech company focused on gastrointestinal disease management and related therapeutic areas. The company develops pharmaceutical and device-based solutions for conditions such as liver disorders, gastrointestinal oncology, and colorectal care. Its portfolio includes Aramchol, an oral therapeutic candidate being developed for liver-related indications, as well as medical device technologies designed to support postoperative colorectal treatment. Eocene Ltd. combines research, clinical development, and product commercialization activities across its healthcare platform, with operations centered in Ramat Gan, Israel. The company serves a niche role in the biotechnology market by pursuing therapies and technologies aimed at unmet needs in gastrointestinal and adjacent medical fields.

CEO Mr. Allen Baharaff · 3 employees · Israel · https://galmedpharma.com